In a subsequent in vivo study performed on a B16-uPAR mouse allograft model, ARM-U2 suppressed tumor progression, showing comparable effectiveness to the standard-of-care agent Dox, but without the substantial weight loss associated with this treatment, thus indicating an increase in selectivity and potentially improved side-effect profile, conferred by the active uPAR-targeting [257]. This evidence concerns the gene PLAUR and neoplasm.